-
Psoralen-Induced Cholestasis via ERK1/2
2026-08-10
Chen et al. show that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, produce cholestatic liver injury in zebrafish larvae through ERK1/2 activation. By combining estrogenic, hepatobiliary, gene-expression, and pharmacologic rescue assays, the study identifies ERK1/2 as a mechanistically testable node in phytoestrogen-induced cholestasis.
-
Amyloid β-Peptide (1-42): Applied Assay Workflows
2026-08-09
Build more reproducible Alzheimer’s disease models with Aβ42 peptide workflows that connect aggregation, neuronal toxicity, ion-channel physiology, and fibril imaging. This guide combines practical handling advice with a ratiometric imaging strategy for separating amyloid signal from common fluorescence variability.
-
Alosetron: 5-HT3 Research Mechanism & Workflow
2026-08-08
Alosetron is a selective 5-HT3 receptor antagonist for controlled serotonin receptor pharmacology and gastrointestinal research. Its product specifications support DMSO-based preparation, −20°C storage, and research-use-only workflows, while intestinal polarity findings provide a mechanistic context rather than direct evidence for alosetron activity.
-
gamma-Glu-Cys: Glutathione Research Guide
2026-08-07
gamma-Glu-Cys (γ-Glu-Cys) is a defined L-glutathione biosynthesis intermediate and substrate for glutathione synthetase research. The B7887 product combines approximately 98% HPLC purity with high reported solubility, while assay users must distinguish biochemical substrate performance from cellular or plant-level effects.
-
Lipidated Nanophotosensitizers Block Tumor EVs to Suppress M
2026-08-07
This study introduces a lipidated nanophotosensitizer capable of both tracing and disabling tumor extracellular vesicles (TEVs), achieving concurrent inhibition of tumor growth and metastasis in vivo. The findings set a new paradigm for selective TEV-targeted interventions, with significant implications for membrane trafficking and exocytic pathway research.
-
Mc-Val-Cit-PABC-PNP: Practical Guide for ADC Linker Use
2026-08-06
Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable ADC peptide linker designed for precise, lysosomal-triggered payload release in antibody-drug conjugate (ADC) synthesis. It is intended for organic solvent-based workflows and should not be used for aqueous, diagnostic, or clinical applications.
-
U0126-EtOH: Precision MEK1/2 Inhibitor for MAPK/ERK Modulati
2026-08-06
U0126-EtOH from APExBIO empowers researchers to dissect MAPK/ERK signaling with unparalleled selectivity, enabling robust neuroprotection and inflammation assays. Discover protocol optimizations, troubleshooting strategies, and insights drawn from cutting-edge paraptosis research.
-
CRTC-CREB Axis Senses Proteotoxic Stress via ROS/JNK in Dros
2026-08-05
This study demonstrates that proteasome inhibition, including by MLN2238, robustly activates the CRTC-CREB axis in Drosophila through ROS/JNK signaling. The findings reveal a conserved transcriptional response to proteotoxic and oxidative stress, with implications for research on neurodegeneration and protein aggregation.
-
Synergistic Antitumor Immunity: Radiotherapy with PD-1/TIGIT
2026-08-05
This study demonstrates that combining radiotherapy with PD-1 and TIGIT immune checkpoint blockade produces robust abscopal antitumor effects and durable immune memory via CD8+ T cells. The mechanistic insights highlight the pivotal role of M1 macrophage polarization and NF-κB pathway activation in mediating these responses, offering a framework for overcoming immune resistance in cancer therapy.
-
AM 281: Applied Workflows for CB1 Cannabinoid Receptor Antag
2026-08-04
AM 281 stands out as a nanomolar-potency, highly selective CB1 cannabinoid receptor antagonist, enabling precise interrogation of endocannabinoid signaling in cognitive dysfunction and brain injury models. This article translates recent mechanistic advances into practical workflows, protocol optimizations, and troubleshooting strategies for neuropharmacology researchers using AM 281 from APExBIO.
-
Risedronate Sodium: FPP Synthase Inhibitor for Bone Metaboli
2026-08-04
Risedronate Sodium stands out as a potent FPP synthase inhibitor, enabling precise control of osteoclast-mediated bone resorption and experimental modeling of bone and pulmonary disease. Applied in cell assays and animal studies, its reproducible effects and diverse delivery options give researchers a robust toolkit for advancing bone metabolism and cancer research.
-
Capsaicin: Bridging TRPV1 and KDM1A for Translational Impact
2026-08-03
This article provides a mechanistic and strategic roadmap for translational researchers leveraging (E)-Capsaicin. By integrating insights on TRPV1 ion channel activation and KDM1A/LSD1 inhibition, and referencing new evidence on nociceptor modulation, the discussion advances beyond standard product pages to address challenges in pain, inflammation, itch, and oncology models. Protocol guidance, competitive context, and clinical implications are interwoven, positioning APExBIO's Capsaicin as a pivotal tool for cross-domain innovation.
-
Palomid 529 in ESCC: Protocols, Advantages, and Troubleshoot
2026-08-03
Palomid 529 (P529) enables targeted inhibition of the PI3K/Akt/mTOR pathway, providing researchers with a powerful tool to dissect mechanisms of metastasis and drug resistance in esophageal squamous cell carcinoma (ESCC). This guide translates recent mechanistic breakthroughs into actionable workflows, troubleshooting insights, and comparative advantages for cancer and radiotherapy research.
-
uPAR-uPA Inhibition: Advances in Metastasis Blocking Strateg
2026-08-02
This study presents a thorough biochemical and in vivo analysis of a small molecule inhibitor targeting the uPAR-uPA interaction, a driver of breast cancer metastasis. The findings demonstrate direct binding, functional inhibition of invasion and migration, and significant reduction of metastatic spread in murine models, providing a promising scaffold for future anti-metastatic therapies.
-
Simvastatin Induces Autophagy and Inhibits Prostate Cancer G
2026-08-01
This study demonstrates that Simvastatin triggers autophagy and suppresses proliferation in multiple prostate cancer cell lines, suggesting a promising mechanism for targeting castration-resistant prostate cancer (CRPC). The findings provide actionable insights for researchers exploring statins as anti-cancer agents beyond their established role in cholesterol metabolism.